Clinical course and immune status in patients 4, 5, and 6 before and after EBV-specific T-cell transfer. Data are shown for patient 4 (A-B), patient 5 (C-F), and patient 6 (G-J). (A,C,G) EBV DNA levels in peripheral blood cells (copies per 20 000 cells), in throat lavage fluid (copies per milliliter), and in endotracheal suctioning (copies per milliliter). (B,D,H) Serum levels of transaminases (GOT indicates glutamic-oxaloacetic transaminase; GPT, glutamic-pyruvic transaminase) are expressed in U/L. (E,I) Absolute numbers of CD8⁺ and CD4⁺ T-cell subsets in peripheral blood. For patient 4, no data near the time of T-cell transfer were available. (F) Peripheral blood cells from patient 5 (day −13 and day 4) were stained with HLA-peptide pentamers for the EBNA3A epitope RLR or the irrelevant (mismatched) epitope EPL (see Table 5). In analysis, cells were gated on large lymphocytes. The proportion of pentamer-staining cells is shown. (J) Peripheral blood cells from patient 6 (day 6 after T-cell transfer) were tested in an IFN-γ ELISPOT assay for recognition of the matched EBV peptide RRIY, the mismatched peptide IPQC, or the mix of 23 EBV peptides. Negative control was without peptide, positive control was TPA (12-O-tetradecanoylphorbol-13-acetate) and ionomycin. (A-I) Indicated days are relative to T-cell transfer (day 0).